跳转至内容
Merck
CN

SML0234

Mitiglinide calcium

≥98% (HPLC)

别名:

(aS,3aR,7aS)-Octahydro-g-oxo-a-(phenylmethyl)-2H-isoindole-2-butanoic acid calcium salt, KAD 1229, Mitiglinide hemicalcium salt, S 21403, [2(S)-cis]-Octahydro-g-oxo-a-(phenylmethyl)-2H-isoindole-2-butanoic acid calclium salt

登录 查看组织和合同定价。

选择尺寸


关于此项目

经验公式(希尔记法):
C19H24NO3·0.5Ca
化学文摘社编号:
分子量:
334.44
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
12352200
MDL number:
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

InChI

1S/2C19H25NO3.Ca/c2*21-18(20-12-15-8-4-5-9-16(15)13-20)11-17(19(22)23)10-14-6-2-1-3-7-14;/h2*1-3,6-7,15-17H,4-5,8-13H2,(H,22,23);/q;;+2/p-2/t2*15-,16+,17-;/m00./s1

SMILES string

O=C(C[C@H](Cc1ccccc1)C(=O)O[Ca]OC(=O)[C@H](CC(=O)N2C[C@H]3CCCC[C@H]3C2)Cc4ccccc4)N5C[C@H]6CCCC[C@H]6C5

InChI key

PMRVFZXOCRHXFE-FMEJWYFOSA-L

assay

≥98% (HPLC)

form

powder

optical activity

[α]/D +5 to +9° (c=1, MeOH)

storage condition

desiccated

color

white to beige

solubility

DMSO: ≥10 mg/mL at warmed to 60 °C

storage temp.

room temp

Quality Level

Biochem/physiol Actions

Mitiglinide calcium is a highly selective KATP channel antagonist
Mitiglinide is a drug for the treatment of type 2 diabetes. It is a highly selective KATP channel antagonist Mitiglinide is a hypoglycemic agent that closes adenosine triphosphate (ATP)–sensitive potassium channels (KATP channel s) in the pancreatic β-islet cells.

Features and Benefits

This compound is featured on the Potassium Channels page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

存储类别

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

法规信息

新产品
此项目有

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Jin Ah Jung et al.
Clinical drug investigation, 32(12), 799-804 (2012-10-27)
In the treatment of diabetes mellitus, combined drugs with different mechanisms of action can be effective when adequate glycaemic control is difficult with monotherapy. A fixed-dose combination (FDC) tablet of mitiglinide and metformin has been developed as a second-line treatment
H Konya et al.
The Journal of international medical research, 37(6), 1904-1912 (2010-02-12)
This study investigated the effects of mitiglinide in 16 patients with type 2 diabetes mellitus treated with 30 mg/day mitiglinide, divided into three doses given just before each meal, for approximately 12 months. A 450 kcal meal tolerance test was
Masanori Abe et al.
Endocrine journal, 57(7), 579-586 (2010-05-15)
Mitiglinide is a rapid- and short-acting insulinotropic sulfonylurea receptor ligand and features rapid hypoglycemic action. To date, no prospective study has evaluated the use of mitiglinide in diabetic patients receiving hemodialysis (HD). In this study we evaluated the efficacy and
Haley M Phillippe et al.
The Annals of pharmacotherapy, 44(10), 1615-1623 (2010-09-16)
To review the pharmacology, pharmacokinetics, efficacy, and safety of mitiglinide, a rapid-acting insulin secretion-stimulating agent to determine its potential role in therapy for the treatment of type 2 diabetes mellitus. A MEDLINE search (1966-May 2010) was conducted for English-language, human
Hind Hadi et al.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 895-896, 131-136 (2012-04-17)
A hollow fiber liquid phase microextraction (HF-LPME) in conjunction with reversed phase HPLC-UV method was developed for the extraction and determination of trace amounts of the antidiabetic drug, mitiglinide (MIT) in biological fluids. The drug was extracted from 10 mL

商品

We offer many products related to potassium channels for your research needs.

我们可提供多种与钙通道相关的产品以满足您的各类研究需求。

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持